A photo of Rebecca Marsh.

Clinical Director, Primary Immune Deficiency Program

Co-Director, Diagnostic Immunology Laboratories

Clinical Director, HLH Center of Excellence

Professor, UC Department of Pediatrics


Board Certified

"Each patient and family is different, and I enjoy getting to know each person and helping them live their best life through optimal treatment of their immune deficiency."

My Biography & Research


I’ve always been fascinated by the immune system and also felt a calling to pediatrics. I enjoy working with people and developing long-term relationships with patients and families, so my career in primary immune deficiencies and hematopoietic cell transplantation is a perfect fit. My practice combines my love of immunology with caring for pediatric patients and working in a team-based setting.

As an immunologist and transplant physician, I treat patients with primary immune deficiencies and immune regulatory diseases, which are collectively called inborn errors of immunity. I’m the clinical director of the Primary Immune Deficiency Program and co-director of Diagnostic Immunology Laboratory.

Our practice provides a variety of treatments for patients, including allogeneic hematopoietic cell transplantation. Each patient and family is different, and I enjoy getting to know each person and helping them live their best life through optimal treatment of their immune deficiency.

We have a large group of specialists in the diagnosis and treatment of inborn errors of immunity. We also have the largest clinical laboratory specializing in primary immunodeficiency diagnostics. Our physician group consists of several experts in primary immunodeficiencies. Our physicians not only provide state-of-the-art treatment for patients, but they also lead the field with primary immune deficiency research and new treatment trials.

We have many nurse practitioners dedicated to caring for patients with inborn errors of immunity. Patients in our practice also work with a dedicated nurse coordinator who helps patients navigate their medical care. Our practice is special because we provide cutting-edge diagnostics and treatments for our patients and also maintain a supportive and caring team-based environment.

Through my research, I want to improve allogeneic hematopoietic cell transplantation for patients with primary immunodeficiencies. I’m also working to improve the treatment of patients with X-linked inhibitor of apoptosis (XIAP) deficiency and hemophagocytic lymphohistiocytosis (HLH).

In my free time, I like to play the piano, bake and spend time with my family.

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Immune Deficiencies and Histiocytosis, Bone Marrow Transplantation BMT, 22Q-VCFS, Hemophagocytic lymphohistiocytosisHLH

Research Divisions

Bone Marrow Transplantation, Cancer and Blood Diseases

My Education

BS: University of Tennessee, Knoxville, TN, 1998.

MD: Rush Medical College, Chicago, IL, 2003.

Residency: Rush University Medical Center, Chicago, IL, 2006.

Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2008.

My Publications

The Natural History of X-Linked Lymphoproliferative Disease (XLP1): Lessons from a Long-Term Survivor. Jiang, Y; Firan, M; Nandiwada, SL; Reyes, A; Marsh, RA; Vogel, TP; Hajjar, J. Case Reports in Immunology. 2020; 2020:8841571-9.

CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. Khandelwal, P; Fukuda, T; Teusink-Cross, A; Kashuba, AD M; Lane, A; Mehta, PA; Marsh, RA; Jordan, MB; Grimley, MS; Myers, KC; et al. Bone Marrow Transplantation. 2020; 55:1552-1559.

Neuroinflammatory Disease as an Isolated Manifestation of Hemophagocytic Lymphohistiocytosis. Blincoe, A; Heeg, M; Campbell, PK; Hines, M; Khojah, A; Klein-Gitelman, M; Talano, J; Speckmann, C; Touzot, F; Lankester, A; et al. Journal of Clinical Immunology. 2020; 40:901-916.

Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders. Vander Lugt, MT; Chen, X; Escolar, ML; Carella, BA; Barnum, JL; Windreich, RM; Hill, MJ; Poe, M; Marsh, RA; Stanczak, H; et al. Blood Advances. 2020; 4:3041-3052.

Frequency and spectrum of disease-causing variants in 1892 patients with suspected genetic HLH disorders. Gadoury-Levesque, V; Dong, L; Su, R; Chen, J; Zhang, K; Risma, KA; Marsh, RA; Sun, M. Blood Advances. 2020; 4:2578-2594.

Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience. Teusink-Cross, A; Davies, SM; Grimley, MS; Chandra, S; Flannery, A; Dandoy, CE; Nelson, AS; Marsh, RA; Jacoby, B; Lane, A; et al. Pediatric Transplantation. 2020; 24.

Pediatric hemophagocytic lymphohistiocytosis. Canna, SW; Marsh, RA. Blood. 2020; 135:1332-1343.

Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Chan, AY; Leiding, JW; Liu, X; Logan, BR; Burroughs, LM; Allenspach, EJ; Skoda-Smith, S; Uzel, G; Notarangelo, LD; Slatter, M; et al. Frontiers in Immunology. 2020; 11.

CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. Khandelwal, P; Chaturvedi, V; Owsley, E; Lane, A; Heyenbruch, D; Lutzko, CM; Leemhuis, T; Grimley, MS; Nelson, AS; Davies, SM; et al. Biology of Blood and Marrow Transplantation. 2020; 26:1-6.

The Value of Chromosome Analysis to Interrogate Variants in DNMT3B Causing Immunodeficiency, Centromeric Instability, and Facial Anomaly Syndrome Type I (ICF1). Kellner, ES; Rathbun, PA; Marshall, GS; Tolusso, LK; Smolarek, TA; Sun, M; Chandra, S; Bleesing, J; Marsh, RA. Journal of Clinical Immunology. 2019; 39:857-859.